Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19

Sarah C.J. Jorgensen, Christopher L.Y. Tse, Lisa Burry, and Linda D. Dresser

Department of Pharmacy, Sinai Health System, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; Antimicrobial Stewardship Program, University Health Network, Toronto, Ontario, Canada

A hyperinflammatory response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, reminiscent of cytokine release syndrome, has been implicated in the pathophysiology of acute respiratory distress syndrome and organ damage in patients with coronavirus disease 2019 (COVID-19). Agents that inhibit components of the pro-inflammatory cascade have garnered interest as potential treatment options with hopes that dampening the proinflammatory process may improve clinical outcomes. Baricitinib is a reversible Janus-associated kinase (JAK)-inhibitor that interrupts the signaling of multiple cytokines implicated in COVID-19 immunopathology. It may also have antiviral effects by targeting host factors that viruses rely for cell entry and by suppressing type I interferon driven angiotensin-converting-enzyme-2 upregulation. However, baricitinib’s immunosuppressive effects may be detrimental during acute viral infections by delaying viral clearance and increasing vulnerability to secondary opportunistic infections. The lack of reliable biomarkers to monitor patients’ immune status as illness evolves complicates deployment of immunosuppressive drugs like baricitinib. Furthermore, baricitinib carries the risk of increased thromboembolic events, which is concerning given the proclivity towards a hypercoagulable state in patients with COVID-19. In this article, we review available data on baricitinib with an emphasis on immunosuppressive and antiviral pharmacology, pharmacokinetics, safety, and current progress in COVID-19 clinical trials.

Keywords: baricitinib, Janus-associated kinase inhibitor, JAK-inhibitor, COVID-19, SARS-CoV-2, severe acute respiratory syndrome.

Pharmacotherapy 2020;40(8):843–856 doi: 10.1002/phar.2438

Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease, coronavirus disease 2019 (COVID-19), experience a wide spectrum of clinical manifestations and illness severity. Although most symptomatic patients have a relatively mild clinical course, ~20% require hospitalization and 20% of those hospitalized will be admitted to the intensive care unit (ICU). In some patients, a sudden and rapid clinical deterioration manifesting as acute respiratory distress syndrome and multiorgan failure has been observed around day 7–10 of hospitalization. Interestingly, clinical deterioration often occurs when viral titers are declining leading some to postulate that an over exuberant immune response may be involved in the underlying pathophysiology of organ damage. This theory is supported by the correlation between COVID-19 complications and elevated levels of acute
phase reactants, coagulation abnormalities, and hypercytokinemia, reminiscent of cytokine release syndrome. A number of agents that inhibit one or more components of the proinflammatory cascade are now being investigated in clinical trials with hopes that blunting this process may improve clinical outcomes.

The use of immunosuppressive drugs during an acute viral illness carries the risk of delaying viral clearance and increasing vulnerability to secondary opportunistic infections. Coupling these drugs with effective antiviral agents, either sequentially or concurrently, may therefore be essential for positive patient outcomes.

Antiviral drug discovery has traditionally focused on designing compounds that target essential viral components, including viral proteases or polymerases. This approach has been successful for chronic viral infections, such as HIV and hepatitis C. However, direct-acting antivirals are typically narrow in spectrum, take years or even decades to develop, and may have a low barrier to resistance when used as monotherapy.

Baricitinib (C\textsubscript{16}H\textsubscript{17}N\textsubscript{7}O\textsubscript{2}S, formerly LY3009104) is a small molecule reversible Janus-associated kinase (JAK)-inhibitor approved in over 65 countries for the treatment of adults with moderate to severe rheumatoid arthritis (RA). The JAK/signal transducers and activators of transcription (STAT)-pathway mediates signal transduction from extracellular stimuli, including cytokines, growth factors, and hormones, to the nuclei of cells. Baricitinib exerts its antiinflammatory effects through reversible JAK inhibition, as shown in Figure 1. Signaling is initiated when cytokines bind to their receptor on the cell membrane. This results in conformational changes that trigger activation of associated JAK complexes. JAK activation, in turn, leads to autophosphorylation and subsequent increased JAK kinase activity as well as phosphorylation of the intracellular portion of their cognate receptors. Receptor phosphorylation creates a docking site for signaling molecules especially members of the STAT family. Once docked to the receptor, STAT molecules are also phosphorylated by JAKs. The phosphorylated STATs are then released from the receptor, form homo-dimers or hetero-dimers through reciprocal interactions with their newly phosphorylated tyrosine domains, and translocate to the cell nucleus where they bind to specific DNA sequences to activate target gene transcription.

The JAK family is comprised of four cytoplasmic protein tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2).
Cytokine receptors recruit two of the four JAKs to the intracellular domain of the signaling complex (i.e., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, and JAK2/TYK2; Figure 1). Inhibition of one or both JAK monomers associated with the cytokine receptor is typically sufficient to interrupt signal transduction. JAK1, JAK2, and TYK2 are expressed throughout the human body, whereas JAK3 is primarily expressed by hematopoietic cells in the bone marrow. The various JAK complexes mediate distinct cytokine signaling pathways. For example, innate antiviral responses via type I interferon (IFN) are mediated by JAK1/TYK2 and IFN-gamma signaling is mediated by JAK1/JAK2. Interleukin (IL)-6, which has emerged as a strong predictor of poor outcomes in COVID-19, transduces signaling via complexes of JAK1, JAK2, and TYK2.

Baricitinib was designed to selectively inhibit JAK1 and JAK2 with less potency for JAK3. It has been postulated that sparing JAK3 could reduce the immunosuppression associated with pan-JAK inhibition. However, as presented in Table 1, baricitinib's purported selectivity is only evident in cell-free assays but not recapitulated in cell-based assays. Baricitinib 50% inhibitory concentrations (IC_{50}) for JAK complexes that mediate signaling for a wide variety of cytokines implicated in COVID-19 immunopathology generally fall below the free maximum plasma drug concentration (C_{max}) values achieved with approved dosing (Tables 1 and 2).

### Table 1. Antinflammatory and Antiviral Activity of Baricitinib (adapted from references 13,20,24)

| JAK enzymes, cell-free | Baricitinib mean IC_{50}, nM | JAK enzyme pair, cell-based | Baricitinib mean IC_{50}, nM |
|------------------------|-------------------------------|-----------------------------|-------------------------------|
| JAK1                   | 5.9                           | JAK1/JAK2                   | 32.8                          |
| JAK2                   | 5.7                           | JAK1/JAK3                   | 55.4                          |
| JAK3                   | > 400                         | JAK1/TYK2                   | 71.6                          |
| TYK2                   | 53                            | JAK2/TYK2                   | 69.0                          |

| NAK enzymes, cell-free | Baricitinib K_{d}, nM | NAK enzymes, cell-based | Baricitinib K_{d}, nM |
|------------------------|-----------------------|-------------------------|-----------------------|
| AAK1                   | 17                    | AAK1                    | 34                    |
| GAK                    | 136                   | GAK                     | 272                   |

AAK1 = AP2-associated protein kinase 1; GAK = cyclin G-associated kinase; IC_{50} = 50% inhibitory concentrations; JAK = Janus-associated kinase; K_{d} = dissociation constant; NAK = numb-associated kinase; TYK2 = tyrosine kinase 2.

Antiviral Activity

Baricitinib may also have antiviral activity. Its potential antiviral activity was
identified by searching a large repository of structured medical and drug information extracted using machine learning (BenevolentAI, London, UK). Nearly 50 currently approved drugs for a variety of indications from oncology to autoimmune disorders were identified by this approach as inhibitors of host enzymes involved in regulating intracellular viral trafficking. Only baricitinib, however, showed inhibitory activity at clinically achievable serum concentrations.

Many viruses gain entry into human cells by hijacking host-derived membrane trafficking processes; one of the most well studied is clathrin-mediated endocytosis. Clathrin is an endocytic coat protein that clusters on the inner leaflet of the plasma membrane to form the initial spherical cage-like vesicle structure involved in endocytosis. Viral internalization via clathrin-mediated endocytosis is shown in Figure 2. The process is initiated when the virus binds to the host cell surface receptor (angiotensin-converting enzyme 2 [ACE2]) in the case of SARS-CoV-2, although in murine infection models the combination of both sunitinib and erlotinib (an anticancer drug that inhibits AAK1) and GAK (an anticancer drug that inhibits GAK) was required to protect mice from lethal Ebola and dengue virus challenges. It should also be pointed out that SARS-CoV-1 uses several different endocytic pathways for viral entry and if this is also true for SARS-CoV-2, baricitinib’s inhibition of clathrin-mediated endocytosis could be circumvented by use of an alternative pathway.

An additional antiviral mechanism related to baricitinib’s inhibitory effect on IFN signaling has been proposed. As noted above, IFN responses are essential host antiviral defenses but recent work has revealed that type I IFN and to a lesser extent type II IFN upregulate ACE2 expression in multiple human cell lines, including upper airway epithelial cells and primary bronchial cells. However, ACE2 is also counter-regulatory to the renin-angiotensin-aldosterone system (RAAS) and has a protective effect against RAAS-related organ damage, including acute lung injury. One of SARS-CoV-2’s key virulence factors is its ability to downregulate ACE2 expression after cell entry, thereby thwarting ACE2 lung-protective effects. It is conceivable that baricitinib’s suppression of type I IFN signaling could amplify ACE2 downregulation, further diminishing its protective effects. The net effect of IFN suppression (beneficial vs. detrimental) in the setting of COVID-19 might depend on the underlying immune status of the patient and the stage of infection.

**Pharmacokinetics**

Table 2 summarizes pertinent baricitinib PK parameters, which were derived from single and multiple-dose studies in healthy adult volunteers.

| Parameter | Value |
|-----------|-------|
| C<sub>max,ss</sub> | Total 53.4 ng/ml; Free 26.7 ng/ml |
| C<sub>min,ss</sub> | Total 143.8 nM; Free 71.9 nM |
| AUC<sub>24</sub> | 477.6 ng·hr/ml |
| Bioavailability | 79% |
| V<sub>d</sub> | 75.7 L |
| Free fraction | 50% |
| T<sub>1/2</sub> | Healthy subjects 6–9 hrs; Patients with RA hrs |

AUC<sub>24</sub> = area under the concentration time curve over 24 hours; C<sub>max,ss</sub> = maximal concentration at steady state; C<sub>min,ss</sub> = minimum concentration at steady state; JAK = Janus-associated kinase; RA = rheumatoid arthritis; T<sub>1/2</sub> = half-life; V<sub>d</sub> = volume of distribution.

Table 2. Pharmacokinetic Parameters of Baricitinib 4 mg Orally Once Daily (Adapted from references 1,3,25,26)
and patients with RA.\textsuperscript{25,26,35} After oral administration, baricitinib is rapidly absorbed reaching peak plasma concentrations within 60 minutes.\textsuperscript{25,26} The absolute bioavailability is 79% and food has minimal impact on PK parameters.\textsuperscript{25,26} Baricitinib exhibits linear dose proportional PK after single oral doses between 1 mg and 20 mg with minimal accumulation for up to 28 days.\textsuperscript{26,35} Both C\textsubscript{max} and area under the concentration time curve over 24 hours (AUC\textsubscript{24}) values increase \~60% and 75% in patients with RA compared with healthy subjects, respectively, and interindividual variability is higher in patients with RA.\textsuperscript{25,26} Exposure is also increased greater than 2-fold in those with moderate to severe renal impairment and end-stage renal disease (ESRD).\textsuperscript{25,26} Exposure in patients with COVID-19 or other acute viral infections has not been reported at this time (acute infection at baseline was a contraindication for all RA clinical trials).\textsuperscript{10} As shown in Tables 1 and 2, baricitinib free C\textsubscript{max} values with 4 mg once daily dosing exceed IC\textsubscript{50} values for inhibition of cytokine-induced JAK/STAT signaling in cell-free and cell-based assays and concentrations also exceed the dissociation constant (K\textsubscript{d}) for AAK1 but supratherapeutic levels may be required to inhibit GAK.\textsuperscript{13,24,25} Additionally, PK modeling of 4 mg once daily dosing showed that there is a 12-hour window when baricitinib serum levels fall below IC\textsubscript{30} values for JAK complexes.\textsuperscript{25} The clinical implications of this in the setting of COVID-19-related cytokine storm are unclear.

Plasma protein binding for baricitinib is 50% and is not concentration dependent. The mean volume of distribution is 1.1 L/kg, suggesting moderate distribution into tissues.\textsuperscript{25,26} Epithelial lining fluid concentrations have not been reported.

Baricitinib is primarily cleared by renal elimination through both filtration and active secretion.\textsuperscript{25,26} Approximately 75% is excreted in the urine (69% unchanged) and 20% in the feces (15% unchanged).\textsuperscript{25,26} The half-life is 6–9 hours in healthy volunteers but increases to 12 hours in patients with RA and 19 hours in subjects with severe renal impairment or ESRD.\textsuperscript{25,26} Baricitinib is effectively dialyzed with a mean clearance by hemodialysis of 6 L/h.\textsuperscript{26} The impact of continuous renal replacement therapy and extracorporeal membrane oxygenation on baricitinib PK has not been described at this time. In population PK analyses, body weight did not have a clinically meaningful impact on baricitinib clearance, however, obese patients with RA have been reported to have lower response rates.\textsuperscript{3,26,36,37} As discussed in the Drug Interactions section, baricitinib is a substrate of several drug transporters that impact absorption, distribution, and elimination.\textsuperscript{26}

Only a small fraction (6%) of baricitinib is metabolized, predominantly by CYP3A4, and
there is no clinically relevant difference in baricitinib exposure in patients with moderate hepatic function (Child-Pugh B).26

Baricitinib PK has been evaluated in a small number of pediatric patients (n=18, mean age 12.5 years, weight 9.2–84.3 kg) who received the drug through a compassionate use program for rare Mendelian autoinflammatory diseases.38 Weight and renal function significantly influenced volume of distribution and clearance, respectively, suggesting the need for weight and renal function based dosing. Importantly the half-life of baricitinib was significantly shorter in children, especially among those weighing less than 40 kg, and the authors of this study recommended twice daily to four times daily dosing in children depending on renal function.38

Pharmacokinetics parameters in pregnant or breastfeeding women have not been reported at this time. It is not known if baricitinib crosses the placenta in humans. Skeletal malformations and developmental toxicity have been observed in the offspring of pregnant rats exposed to supratherapeutic doses of baricitinib.24 Effects on fertility in animals have been inconsistent.24

Drug-drug interactions

Baricitinib is not an inhibitor or inducer of CYP450 enzymes or drug transporters (P-glycoprotein, BCRP, OATP1B1, OATP1B3, OCT 1–3, MATE-1, and MATE2-K) at clinically relevant concentrations.25,26 Although a small fraction (6%) of baricitinib is metabolized by CYP3A4, co-administration with ketoconazole (a strong CYP3A4 inhibitor) or rifampin (a strong CYP3A4 inducer) did not have a clinically meaningful impact on baricitinib PK.25,26

As noted in the PK section, baricitinib is a substrate of several drug transporters (P-glycoprotein, BCRP, MATE2-K, and OAT3).25,26 Co-administration with cyclosporine (P-glycoprotein inhibitor) did not result in clinically relevant changes to baricitinib PK, however, co-administration with probenecid (a strong OAT3 inhibitor) led to decreased renal clearance and an ~2-fold increase in AUC.25,26 Dose reduction is recommended in patients taking strong OAT3 inhibitors (see Section Dosage and Administration).25,26 Based on PK modeling, less potent OAT3 inhibitors, such as ibuprofen and diclofenac, are expected to have minimal impact on baricitinib PK.26 Studies examining the impact of BCRP or MATEK-2 inhibitors have not been reported at this time. Increased gastric pH and the use of proton-pump inhibitors do not alter overall exposure to baricitinib although the time to peak plasma concentrations was prolonged to 2 hours with concomitant administration of omeprazole.26 No signal of rate-corrected QT (QTc) interval prolongation has been observed with baricitinib doses up to 40 mg in healthy volunteers.38,39

Clinical Experience for COVID-19

Baricitinib is under investigation in multiple ongoing clinical studies (Table 3), including the second iteration of the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT-2).30,31 ACTT-2 is an adaptive, randomized, double-blind, active-controlled multinational study.31 Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection and one of the following are eligible for enrollment: infiltrates on chest imaging, an oxygen saturation less than or equal to 94% on room air, need for supplemental oxygen, or need for mechanical ventilation.41 The primary end point is time to recovery within 28 days after randomization using a 3-point ordinal scale.41 In the first iteration of the study (ACTT-1), patients were randomized to the antiviral drug, remdesivir, or placebo.36 Preliminary results were recently published after enrolling over 1000 patients: the median time to recovery was significantly shorter in the remdesivir group (11 days vs 15 days, hazard ratio 1.32; 95% confidence interval 1.12–1.55).36 Moving forward in ACTT-2, all patients will receive remdesivir and additionally be randomized to baricitinib 4 mg daily or placebo for up to 14 days.41

The off-label use of baricitinib in patients with COVID-19 was recently reported in a small before and after study of patients at centers in the Northern Italian province of Prato.42 This study included consecutive patients hospitalized between March 16 and 30, 2020 with moderate COVID-19 defined as a positive SAR-CoV-2 realtime polymerase chain reaction (RT-PCR) nasopharyngeal or oropharyngeal swab, evidence of pneumonia on chest imaging, and fever, cough, myalgia, or fatigue. Patients (n=12) were treated with lopinavir/ritonavir (250 mg twice daily) plus baricitinib (4 mg daily) for 14 days. Those with thrombophlebitis, latent tuberculosis, and pregnant or breastfeeding women were excluded. An equal number of patients with moderate COVID-19 admitted in the week preceding this period served as the control group.
| ClinicalTrials.gov identifier | Study design | Intervention/treatment of interest | Location | Primary outcome | Target sample size | Sponsor |
|-----------------------------|--------------|----------------------------------|----------|----------------|-------------------|---------|
| NCT04280705                | Adaptive, randomized, multicenter, double-blind, placebo-controlled | • Remdesivir i.v. 200 mg day 1 then 100 mg days 2–10 × 10 days PLUS one of:  
  • Baricitinib 4 mg p.o. o.d. × 14 days  
  • Placebo × 14 days | Multinational | Time to recovery through day 29 according to 3-point ordinal scale | 1000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04340232                | Prospective, single-arm, single-center, open-label | • Baricitinib 2 mg p.o. o.d. × 14 days | USA | Grade 3 or 4 adverse events | 80 | University of Colorado |
| NCT04390464                | Randomized, multicenter, parallel assignment, open-label | • Baricitinib 4 mg p.o. o.d. × 14 days  
  • Ravulizumab IV (weight-based dosing) on day 1  
  • Standard of care | UK | Time to composite end point up to day 14 defined as 1 of: death, mechanical ventilation, ECMO, CV support, or renal failure | 1167 | Cambridge University Hospitals NHS Foundation Trust |
| NCT04362943                | Retrospective, observational, single-center cohort study | • Baricitinib | Spain | All-cause mortality | 576 | Complejo Hospitalario Albacete |
| NCT04346147                | Randomized, single-center, parallel assignment, open-label | • Hydroxychloroquine 200 mg p.o. b.i.d. × 7 days PLUS one of:  
  • Baricitinib 4 mg p.o. o.d. × 7 days Lopinavir/ritonavir  
  • 200/50 mg p.o. o.d. × 7 days  
  • Imatinib 400 mg p.o. o.d. × 7 days | Spain | Time to clinical improvement on 7-point ordinal scale | 165 | Hospital Universitario de Fuenlabrada |
| NCT04320277                | Non-randomized, before-after, single-center | | Italy | ICU transfer | 200 | Hospital of Prato |
| NCT04373044                | Prospective, single-arm, two-center, open-label | • Baricitinib 4 mg p.o. o.d. × 14 days PLUS one of the following at the treating physician’s discretion:  
  • Hydroxychloroquine  
  • Lopinavir/ritonavir  
  • Remdesivir (doses not reported) | USA | Death or mechanical ventilation at day 14 | 59 | University of Southern California |
All patients in the control group received lopinavir/ritonavir (250 mg twice daily) plus hydroxychloroquine (400 mg daily) for 14 days.42 Overall, recorded demographics, comorbidities, and baseline signs and symptoms were similar in the two groups.42 The median oxygen saturation was 91–92% and none of the patients resided in the ICU at enrollment. At 2 weeks, most clinical and laboratory parameters had normalized in the baricitinib group, no patients required ICU admission, and 7 patients (58%) were discharged home. In the control group, there was no significant improvement in most clinical and laboratory parameters, four patients (33%) required ICU admission, and one (8%) was discharged home. With regard to safety, no new bacterial, viral, or opportunistic infections were reported in either group. Baricitinib (and lopinavir/ritonavir) was stopped in 1 patient after 10 days due to increased transaminases.42 Platelets increased from a median of 203 × 10⁹/L at baseline to 354 × 10⁹/L at day 14 in patients who received baricitinib (p=0.018). There was no change in platelets over 2 weeks in the control group (see Safety section for further discussion on increased platelets associated with baricitinib).42

The authors of this report rightly acknowledge its main weaknesses, including the lack of a randomized control group and the small sample size.42 The use of a historical control group in an emerging infectious disease is fraught with limitations due to rapidly evolving knowledge and patterns of care. In addition, the use of concomitant antiviral and adjunctive agents complicates interpretation. The small sample size and short duration of follow-up do not allow a meaningful assessment of safety. Finally, although the authors report that antibiotics were only used when bacterial infection was suspected, it is unclear if any were in fact administered; this information is important when interpreting rates of secondary infections.

Safety
Pooled data from 3492 baricitinib exposed patients (7860 patient-years) enrolled in phase II and III RA clinical trials together with long-term extensions of these studies in the baricitinib development program has been used to characterize baricitinib’s safety profile.10,23 One caveat to these analyses is that patients in the placebo or baricitinib 2 mg/day arms of many studies were allowed to crossover to the 4 mg/day group after week 16, which complicates interpretation and raises the possibility that some risks in the 4 mg/day group may be overestimated. Furthermore, as discussed below, although many adverse effects appeared to be dose related, far
fewer patients were exposed to 2 mg/day so there is more uncertainty in relative risk estimates. In ongoing COVID-19 studies, the duration of baricitinib therapy is typically 7–14 days. Safety data by contrast is derived from patients who received baricitinib for months and many adverse effects manifested after prolonged exposures. Finally, all trials excluded patients with acute infections at baseline limiting generalizability for patients with COVID-19.

The most common side effects with baricitinib are upper respiratory tract infection (14–22%), headache (11–24%), and nasopharyngitis (11–18%).

In addition, dose-related changes in multiple laboratory parameters have been observed in patients treated with baricitinib. Many of these have been reported with other JAK-inhibitors and include rapid and sustained decreases in neutrophil and lymphocyte counts, decreases in hemoglobin, small increases in creatinine (< 0.1 mg/dl), increases in lipid parameters, elevations in liver enzymes and bilirubin, and increases in creatine phosphokinase (CPK). Decreases in lymphocyte counts have been associated with higher rates of treatment-emergent infections among patients with RA in clinical trials. Lymphopenia is one of the most prominent laboratory abnormalities in patients with COVID-19 and lower lymphocyte counts have been associated with more severe disease. In addition to being quantitatively reduced, lymphocytes from patients infected with SARS-CoV-2 also show functional exhaustion and decreased functional diversity. The consequences of exacerbating this immunophenotype with baricitinib require further study.

The significance of modest increases in lipid parameters has been difficult to predict; major cardiac events have occurred in a small number of patients in RA trials, most commonly in extension phases after week 52 but a clear link with lipid parameters has not been reported. Patients with preexisting cardiovascular diseases are at increased risk of the most severe COVID-19 complications. Furthermore, myocardial injury has been observed in nearly 30% of hospitalized patients with COVID-19 and is significantly associated with higher short-term mortality. However, in this setting, the underlying pathogenesis of myocardial injury may be related to the proinflammatory response to infection and countering this with baricitinib could conceivably be protective.

Although increases in liver enzymes and bilirubin have been reported with baricitinib, no cases of liver injury satisfying Hy’s law have occurred. Thirteen patients were withdrawn from studies due to liver function test abnormalities (vs one withdrawal with placebo) and patients with transaminase elevations at baseline (> 1.5 × the upper limit of normal) have been excluded from all studies. Many patients who experienced liver function test abnormalities were receiving concomitant hepatotoxic drugs (i.e., methotrexate or isoniazid). In case series, between 2% and 11% of patients with COVID-19 had chronic liver comorbidities and 14–53% had elevated transaminases during the course of the disease (reviewed in ref. 47). Furthermore, higher rates of liver dysfunction have been correlated with more severe COVID-19. Hepatotoxic drug effects may be difficult to detect in these circumstances and clinicians may need to maintain a high index of suspicion.

In the clinical trials program, CPK elevations were not associated with muscle pain or rhabdomyolysis. However, a recent report describes two patients with RA who developed unexplained lower and/or upper extremity muscle pain and joint swelling coupled with moderate CPK elevations after the initiation of baricitinib. In both cases, clinical and biochemical resolution occurred rapidly after baricitinib discontinuation. The mechanism behind baricitinib-associated CPK elevations has not been widely studied, although experimental evidence supports the theory that certain proinflammatory cytokines may block differentiation of myoblasts into mature myocytes. CPK increases observed with JAK inhibitors may, therefore, represent recovery of muscle development and CPK expression.

Increased CPK is correlated has been with mortality in COVID-19 and rhabdomyolysis has been reported as a late complication. The interaction between possible baricitinib-associated CPK elevations and those secondary to COVID-19 requires further study.

Increased platelet counts is a unique baricitinib effect and has not been observed with other JAK-inhibitors.

In fact, small decreases in platelets and occasional thrombocytopenia occur with two other JAK-inhibitors, tofacitinib and upadacitinib. With baricitinib, platelet counts increase rapidly after initiation and peak around week 2 (mean increase 50 × 10^9/L). Thereafter, they decline and stabilize but remain above placebo and comparators for the duration of therapy. Thrombocytosis appears to be dose related but
still occurs with the 2 mg/day dose. No clear temporal or quantitative association between platelet increases and thromboembolic events (discussed below) has been established. The etiology is not known, although the prevailing theory, based on animal experiments, implicates selective JAK2 inhibition in increased circulating thrombopoietin (TPO, the hormone that stimulates megakaryopoiesis and platelet production) levels. TPO signals are transduced by JAK2. Knockout of the Jak2 gene in hematopoietic stem cells (HSCs) results in thrombocytopenia in mice. In contrast, deletion of Jak2 or the TPO receptor gene in megakaryocytes and mature platelets results in thrombocytosis. Megakaryocytes and mature platelets are responsible for internalizing and degrading circulating TPO by a Jak2 dependent mechanism. This is possible that predominant Jak2 inhibition at the level of megakaryocytes and mature platelets may lead to increased circulating TPO resulting in the increased platelet counts seen with baricitinib. Jak-inhibitors that are less selective for Jak2 may act mainly on Jak2 signaling at the level of HSCs to decrease platelet production. Early case series from Wuhan, China, suggested thrombocytopenia was a prominent feature of severe COVID-19. For unclear reasons, later studies and those from other regions have shown normal or even elevated platelet counts in patients with COVID-19. The impact of thrombocytosis secondary to baricitinib in the setting the COVID-19 coagulopathy is difficult to predict.

Besides common side effects and changes in laboratory parameters, baricitinib has been associated with serious adverse effects, including infections, thrombosis, malignancy, gastrointestinal perforations, and major cardiovascular events. Adverse effects of particular relevance to patients with COVID-19 are infection and thrombosis and are expanded upon below.

Overall, the incidence of serious and opportunistic infections in patients with RA treated with Jak-inhibitors is comparable to other biological disease-modifying antirheumatic drugs (DMARDs), however, the risk of viral infections, specifically herpes zoster virus (HZV) reactivation, appears to be higher with Jak-inhibitors. HZV reactivation rates are ~1.5–2-fold higher among patients with RA taking Jak-inhibitors (3.2–4.0 cases/100 patient-years) compared with the general RA population. Other factors associated with decreased cell-mediated immunity, such as older age and concomitant steroid use, amplify this risk. The incidence of HZV and other infections were numerically higher with baricitinib 4 mg/day versus 2 mg/day. Type 1 IFNs orchestrate a critical antiviral defense via the Jak/Stat pathway and their inhibition by baricitinib is thought to be responsible for HSV reactivation. Critically ill patients with COVID-19 demonstrate an impaired type 1 IFN response and the degree of impairment has been correlated with higher viral loads and poor outcomes. Interestingly, type 1 IFN deficiency was associated with an exacerbated inflammatory response with markedly elevated levels of IL-6 and tumor necrosis factor (TNF)-α. These data suggest timing of baricitinib initiation may be important to both avoid amplifying impaired innate immunity and suppress a harmful hyperinflammatory response. An additional concern with baricitinib use in COVID-19 is its inhibition of signaling from mediators of immune restoration (i.e., IL-2 and IL-7), which may make patients more vulnerable to nosocomial infections. Although rates of coinfections or secondary infections in patients with COVID-19 have been low, little is known about incidence with the use of immunosuppressive drugs.

With regard to thrombosis, there was a numerical imbalance in both arterial and venous thromboembolic events (VTEs) not favoring baricitinib-treated patients in pooled safety data, primarily with 4 mg/day. Five VTEs occurred in patients receiving baricitinib 4 mg/day during the first 16 weeks of therapy (compared with zero in the baricitinib 2 mg/day and placebo groups) and additional events continued to accumulate in both the 4 mg/day and 2 mg/day groups with extended follow-up. In total, 39 VTEs have been reported with baricitinib in the clinical trials program (34 at 4 mg/day and 5 at 2 mg/day) compared with none with placebo (VTE incidence rates 0.6/100 patient-year and 0.4/100 patient-year for 4 md/day and 2 md/day, respectively). Twenty-nine arterial thrombotic events have also been reported in patients who received baricitinib (incidence rates 0.5/100 patient-year and 0.3/100 patient-year for 4 md/day and 2 md/day, respectively) versus 1 event with placebo. It should be noted that in population-based observational studies, VTE rates among individuals with RA on DMARDs range from 0.68 to 1.63/100 patient-years, in line with what was observed in the baricitinib RCTs, however, differences in study designs and patient populations make such comparisons
problematic. Furthermore, an increased incidence of thromboembolic events was also recently reported with higher doses of tofacitinib, another JAK-inhibitor used for RA. 

Thrombotic events and other dose-related adverse effects coupled with the absence of a clear efficacy benefit in RA with the 4 mg/day versus 2 mg/day dose were the primary reasons behind the FDAs failure to approve the manufacturer's first submission in 2017. Baricitinib was approved 1 year later but only at the lower 2 mg/day dose. Health Canada has similarly only approved the 2 mg/day dose. Four mg/day has been approved in some European and Asian countries, however (see Dosage and Administration Section).

The coagulation system is closely linked to inflammation through the innate immune system and patients with COVID-19 appear to have an increased proclivity toward immunothrombosis. Common coagulation abnormalities include elevations in D-dimer and fibrinogen and prolonged prothrombin time. Published series also describe what appears to be a higher than expected incidence of VTE. Baricitinib's inhibition of inflammatory mediators that also drive immunothrombosis could have collateral benefits of reducing hypercoagulability; it is equally plausible however that baricitinib's prothrombotic tendencies could be detrimental. Moving forward, thorough baseline risk assessment and use of the minimally effect dose will be important in minimizing iatrogenic harm. Suggested monitoring parameters for patients receiving baricitinib are shown in Table 4.

### Dosage and Administration

When used for RA, baricitinib is taken once daily by mouth with or without food. The recommended starting dose in Europe is 4 mg/day with the option to decrease to 2 mg/day when RA signs and symptoms are controlled. In Canada and the United States, only 2 mg/day is approved. As shown in Table 3, both 2 mg/day and 4 mg/day are being tested in clinical trials. Recommendations for dosage reductions vary by country. The EMA recommends a 50% dose reduction in the following patients: age greater than or equal to 75 years, a history of chronic or recurrent infections, creatinine clearance (CrCl) between 30 ml/min and 60 ml/min, and concomitant use of a strong OAT3-inhibitor. According to current prescribing information, baricitinib should not be initiated and therapy should be interrupted for the following laboratory parameters: absolute lymphocyte count less than 0.5 x 10⁹/L, absolute neutrophil count less than 1 x 10⁹/L, and hemoglobin less than 8 g/ml. Baricitinib is contraindicated in patients with CrCl less than 30 ml/min. Baricitinib is only available as a film-coated, immediate release tablet. There is no published data on the stability and bioavailability of crushed/dissolved tablets or extemporaneously compounded suspensions at this time.

### Discussion

A growing body of evidence suggests that the host immune response to SARS-Cov-2 infection may be critically important in determining outcomes. This has bolstered enthusiasm about treatment strategies aimed at attenuating both pathogen virulence and the proinflammatory phenotype seen in the many critically ill patients with COVID-19. As detailed in this review, baricitinib pairs immunosuppressive properties with antiviral activity making it a logical candidate for further evaluation in COVID-19 clinical trials.

It is unlikely that a single treatment strategy will help all patients with COVID-19 or have the same effect in an individual patient as illness evolves over time. For many years, an uncontrolled proinflammatory response was thought to be the driver of poor outcomes in sepsis.

| Table 4. Laboratory and Clinical Monitoring Parameters While Receiving Baricitinib (adapted from references 10,25,26,39) |
| --- |
| • Serum creatinine |
| • Absolute lymphocyte count<sup>a</sup> |
| • Absolute neutrophil count<sup>b</sup> |
| • Hemoglobin<sup>c</sup> |
| • Platelets |
| • ALT |
| • AST |
| • Bilirubin |
| • CPK |
| • LDL/HDL (if prolonged use) |
| • Signs and symptoms of infection |
| • Signs and symptoms of thromboembolic events |

ALT = alanine aminotransferase; AST = aspartate transaminase; CPK = creatine phosphokinase; HDL = high density lipoprotein; LDL = low density lipoprotein.

<sup>a</sup>When used for rheumatoid arthritis it is recommended to interrupt therapy when the absolute lymphocyte count falls below 500 cells/mm³.

<sup>b</sup>When used for rheumatoid arthritis it is recommended to interrupt therapy when the absolute neutrophil count falls below 1000 cells/mm³.

<sup>c</sup>When used for rheumatoid arthritis it is recommended to interrupt therapy when hemoglobin falls below 8 g/dl.
the basis of this theory and supportive preclinical data, multiple immunosuppressive agents were investigated in sepsis but with uniformly disappointing results.  

We now know that antiinflammatory mediators, which invoke a state of immunosuppression, also contribute to poor outcomes by impairing the host’s ability to clear infection and increasing vulnerability to secondary opportunistic infections.  

Our understanding of the pathogenesis of and immune response to COVID-19 is rapidly evolving and, like sepsis, relative immunodeficiency also appears to be at play.  

At this time, we do not have a reliable way to gauge whether the overruling response is pro or antiinflammatory and this complicates deployment of immunosuppressive drugs like baricitinib. If given to the wrong patient (i.e., a patient with a predominantly immunosuppressed phenotype) or at the wrong time during the illness, these drugs could cause harm by inhibiting the cytokines required for viral clearance (type-I IFNs) or immune restoration (IL-2 and IL-7).

Baricitinib’s association with thromboembolic events is equally concerning in the context of treating patients with COVID-19. Markers of systemic coagulation activation have been widely reported in patients with COVID-19 and a more pronounced prothrombotic state has been correlated with a more severe disease course and poor outcomes. These patients also have multiple thrombotic risk factors related to critical illness and the supportive care they receive. The ability to detect a thrombotic safety signal related to baricitinib may be challenging in patients with COVID-19 because pulmonary embolism symptoms overlap with symptoms of COVID-19 and imaging may not be feasible.

Conclusions

This review highlights the current challenges faced when balancing potential risks and benefits of immunotherapies for patients with COVID-19. Moving forward, it is incumbent on researchers to develop and validate reliable tools to classify and monitor the overall immune status of patients with COVID-19 to help guide appropriate use of drugs like baricitinib.

References

1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323:1574.

2. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020;80:656–665.

3. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

5. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–43.

6. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361(9371):1767–72.

7. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig 2020;130(5):2620–29.

8. McDonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19(6):102537.

9. Jamilou X, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-inflammatory mediators, which invoke a stasis of immunoparalysis, also contribute to poor state.  

10. Center for Drug Evaluation and Research. US Food and Drug Administration. Medical review baricitinib. NDA 207-924. Apr. 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000MedR.pdf. Accessed May 12, 2020.

11. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: far away, so close! Autoimmun Rev 2020;5:102523.

12. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;10223:e30–1.

13. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;4:400–2.

14. Kumar N, Sharma S, Kumar R, et al. Host-directed antiviral therapy. Clin Microbiol Rev 2020;33(3):e00168-19.

15. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013;12:e81355.

16. Burstow NJ, Mohamed Z, Gomaa AI, et al. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39–52.

17. Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis 2020;26(7):1618–20.

18. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatol (Oxford) 2019;58(Suppl_1):i43–54.

19. Pu SY, Xiao F, Schor S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 2018;155:67–75.

20. Richardson PJ, Corbellino M, Stebbing J, Baricitinib for COVID-19: a suitable treatment? — Authors’ reply. Lancet Infect Dis. Online ahead of print. 2020:S1473-3099(20)30270-X. https://doi.org/10.1016/S1473-3099(20)30270-X.

21. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;1:276–87.

22. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors.Curr Opin Immunol. 1998;3:271–8.

23. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;5:320.

24. Center for Drug Evaluation and Research. US Food and Drug Administration. Pharmacology review baricitinib. NDA 207-924. Apr. 2017. https://www.accessdata.fda.gov/drugsatfda_doc
BARICTIONS FOR COVID-19

s/nda/2020/207924Orig1s0000PharmR.pdf. Accessed 12 May 2020.

25. Committee for Medicinal Products for Human Use. European Medicines Agency. Assessment report Olumiant (baricitinib). EMA/CH/004085/0000. 15 Dec. 2016. Available from: https://www.ema.europa.eu/en/documents/assessment-report/olumiant-epar-public-assessment-report_en.pdf. Accessed May 12, 2020.

26. Center for Drug Evaluation and Research. US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review baricitinib. NDA 207-924. Apr. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000PharmR.pdf. Accessed 12 May 2020.

27. Spinelli FR, Conti F, Gadina M. HijAkInG SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol 2020;5(47):eabc3567.

28. Inoue Y, Tanaka N, Tanaka Y, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 2007;16:8722–9.

29. Kaksonen M, Roux A. Mechanism of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2018;3:313–26.

30. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;180(2):271–80.e8.

31. Bekerman E, Neveu G, Shulla A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad spectrum antiviral effects. J Clin Invest 2017;14(4):1338–52.

32. Wang H, Yang P, Liu K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2008;18:290–301.

33. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;180(1):1016–35.e19.

34. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;17:653–9.

35. Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014;12:1354–61.

36. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med 2020;NEJMoa2007764. Online ahead of print. https://doi.org/10.1056/NEJMoa2007764.

37. Meisen Y, Buzanz L, Schneider M. Baricitinib and tocilizumab in real life – does obesity impact response to janus kinase inhibitor therapy in rheumatoid arthritis? [abstract]. Arthritis Rheumatol 2018;70(suppl 10). https://acrabstracts.org/abstract/baricitinib-and-tocilizumab-in-real-life-does-obesity-impact-response-to-janus-kinase-inhibitor-therapy-in-rheumatoid-arthritis.

38. Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther 2018;2:364–73.

39. Arthritis Advisory Committee Meeting FDA Briefing Document. NDA 207924. Baricitinib Janus Kinase (JAK) inhibitor for RA. Eli Lilly and Company (Lilly). 23 April 2018. Available from https://clinicaltrials.gov/ct2/results?cond=COVID19&term=baricitinib&cnty=&state=&city=&dct=.). Accessed May 15, 2020.

40. ClinicalTrials.gov. Available from https://clinicaltrials.gov/ct2/results?cond=COVID19&term=baricitinib&cnty=&state=&city=&dct=. Accessed May 18, 2020.

41. National Institutes of Health. US Department of Health and Human Services News release. NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug-baricitinib for COVID-19 begins. 8 May 2020. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-antiviral-remdesivir-plus-anti-inflammatory-drug-baricitinib-covid-19-begins. Accessed 26 May 2020.
62. Vallejo-Yague E, Weiler S, Micheroli R, Burden AM. Thromboembolic safety reporting of tofacitinib and baricitinib: An analysis of the WHO VigiBase. Online ahead of print. Drug Saf. 2020 Jun 12; Online ahead of print. https://doi.org/10.1007/s40264-020-00958-9.

63. Product monograph Olumiant (baricitinib) tablets. Eli Lilly Canada Inc. April 2020. http://pi.lilly.com/ca/olumiant-ca-pm.pdf. Accessed 15 May 2020.

64. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18 (7):1559–1561.

65. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020 Apr 13. Online ahead of print. https://doi.org/10.1001/jama.2020.6019.

66. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013;3:260–8.

67. Kox WJ, Volk T, Kooi SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26:124–8.

68. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfalfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055–64.

69. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351(9107):929–33.

70. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;8:1430–9.

71. Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995;9:1461–9.